Top Trump administration officials have taken issue with Marty Makary’s management style, pointing to infighting between his ...

The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and ...

Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...